Milestone Pharmaceuticals Inc.(MIST)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
MIST Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Milestone Pharmaceuticals Inc. (MIST), a Healthcare sector company. MIST is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Milestone Pharmaceuticals Inc. reports quarterly revenue of $238.0K, net income of $-26.1M, free cash flow of $-16.1M. Top institutional holders of MIST by reported 13-F value include RTW INVESTMENTS,, Propel Bio Management,, TWO SIGMA INVESTMENTS,, based on the most recent SEC filings. MIST trades on the Nasdaq exchange and files with the SEC under CIK 1408443. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MIST daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Milestone Pharmaceuticals Inc. directly from SEC EDGAR.
Revenue
Q1 2026
$238.0K
Net Income
Q1 2026
$-26.1M
Free Cash Flow
Q1 2026
$-16.1M
ROIC
Q1 2026
-25.1%
D/E Ratio
Q1 2026
1.61
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
-51.9% YoYOperating Income
-47.6% YoYEPS (Diluted)
-11.9% YoYTotal Assets
+50.4% YoYTotal Debt
+7.2% YoYOp. Cash Flow
-70.0% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Net Income | $-63.1M -51.9% | $-41.5M +30.4% | $-59.7M -39.3% | $-42.9M +14.2% | $-50.0M +9.5% | $-55.2M |
| Operating Income | $-62.1M -47.6% | $-42.1M +31.1% | $-61.1M -41.8% | $-43.1M +15.1% | $-50.7M +12.4% | $-57.9M |
| EPS (Diluted) | $-0.75 -11.9% | $-0.67 +51.8% | $-1.39 -36.3% | $-1.02 +40.0% | $-1.70 | — |
| Total Assets | $113.6M +50.4% | $75.5M +0.4% | $75.2M -37.2% | $119.8M -20.1% | $150.0M +21.5% | $123.4M |
| Total Debt | $57.2M +7.2% | $53.4M +7.2% | $49.8M | — | — | $0.00 |
| Operating Cash Flow | $-49.0M -70.0% | $-28.8M +37.9% | $-46.4M -39.7% | $-33.2M +34.5% | $-50.7M +0.8% | $-51.2M |
AI Insight: MIST Ratio Trends
MIST remains deeply unprofitable with no operating or net margin data available, but leverage has eased from a peak D/E of 4.06 in Q4 2024 to 1.37–1.61 in recent quarters.
• D/E ratio peaked at 4.06 in Q4 2024 and has since declined to 1.37 in Q4 2025 and 1.61 in Q1 2026, signaling modest deleveraging.
• ROA deteriorated from -42.0% in Q2 2024 to -65.5% in Q4 2024, though it partially recovered to -53.8% in Q1 2026.
• ROIC worsened from -46.3% in Q2 2024 to -74.3% in Q4 2024; the TTM ROIC stands at -69.3%, indicating persistent capital destruction.
⚠ OpMargin and NPM are unavailable across all periods — absence of revenue-level profitability data makes trend assessment highly limited.
⚠ ROE hit -189.6% on a TTM basis versus -166.7% in Q4 2025, suggesting equity base erosion is accelerating.
Get alerted when MIST's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Milestone Pharmaceuticals Inc. including:
Top Institutional Holders of MIST
RTW INVESTMENTS, LP
$7.5M6,331,001 shPropel Bio Management, LLC
$5.1M4,118,321 shTWO SIGMA INVESTMENTS, LP
$2.8M2,317,176 shGOLDMAN SACHS GROUP INC
$2.4M2,000,025 shMARSHALL WACE, LLP
$2.3M1,944,530 shMILLENNIUM MANAGEMENT LLC
$1.8M1,544,325 shSimplify Asset Management Inc.
$1.8M1,506,405 shPoint72 Asset Management, L.P.
$1.3M1,085,683 shBALYASNY ASSET MANAGEMENT L.P.
$1.0M851,325 shLion Point Capital, LP
$975.8K820,000 sh
| Fund | Value | Shares |
|---|---|---|
| RTW INVESTMENTS, LP | $7.5M | 6,331,001 |
| Propel Bio Management, LLC | $5.1M | 4,118,321 |
| TWO SIGMA INVESTMENTS, LP | $2.8M | 2,317,176 |
| GOLDMAN SACHS GROUP INC | $2.4M | 2,000,025 |
| MARSHALL WACE, LLP | $2.3M | 1,944,530 |
| MILLENNIUM MANAGEMENT LLC | $1.8M | 1,544,325 |
| Simplify Asset Management Inc. | $1.8M | 1,506,405 |
| Point72 Asset Management, L.P. | $1.3M | 1,085,683 |
| BALYASNY ASSET MANAGEMENT L.P. | $1.0M | 851,325 |
| Lion Point Capital, LP | $975.8K | 820,000 |
More Healthcare Companies
View all Healthcare →Put MIST on your watchlist
Track score changes the day Milestone Pharmaceuticals Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MIST a good stock to buy?
13F Pro's AI-powered analysis of Milestone Pharmaceuticals Inc. (MIST) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MIST are available on the MIST stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own MIST?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MIST. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Milestone Pharmaceuticals Inc.'s investment landscape.